Uniqure NV
F:UQ1
Gross Margin
Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.
Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.
Peer Comparison
| Country | Company | Market Cap |
Gross Margin |
||
|---|---|---|---|---|---|
| NL |
|
Uniqure NV
NASDAQ:QURE
|
968.1m USD |
Loading...
|
|
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD |
Loading...
|
|
| US |
|
Abbvie Inc
NYSE:ABBV
|
388.4B USD |
Loading...
|
|
| US |
|
Amgen Inc
NASDAQ:AMGN
|
197.4B USD |
Loading...
|
|
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
179.9B USD |
Loading...
|
|
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
119.2B USD |
Loading...
|
|
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR |
Loading...
|
|
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
78.8B USD |
Loading...
|
|
| AU |
|
CSL Ltd
ASX:CSL
|
67.8B AUD |
Loading...
|
|
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR |
Loading...
|
|
| NL |
|
argenx SE
XBRU:ARGX
|
37.8B EUR |
Loading...
|
Market Distribution
| Min | -3 388.8% |
| 30th Percentile | 29.2% |
| Median | 45.1% |
| 70th Percentile | 64.1% |
| Max | 4 855.5% |
Other Profitability Ratios
Uniqure NV
Glance View
uniQure NV engages in the discovery, development, and commercialization of innovative gene therapies. The company is headquartered in Amsterdam, Noord-Holland and currently employs 463 full-time employees. The company went IPO on 2014-02-05. The company seeks to develop one-time administered treatments with potentially curative results for patients suffering from genetic and other devastating diseases. The company develops, both internally and through partnerships, a pipeline of gene therapies. The company produces adeno-associated virus based, or AAV-based, gene therapies in its own facilities with a proprietary, commercial-scale, current good manufacturing practices, compliant, manufacturing process. AMT-061, the Company’s lead product candidate for patients with hemophilia B, is going through a dosing phase of a pivotal study. AMT-130, the product candidate for patients with Huntington’s disease is in Phase I/II clinical study.
See Also
Gross Margin is calculated by dividing the Gross Profit by the Revenue.
The current Gross Margin for Uniqure NV is 89.5%, which is above its 3-year median of 54%.
Over the last 3 years, Uniqure NV’s Gross Margin has decreased from 96.8% to 89.5%. During this period, it reached a low of -7.3% on Mar 31, 2024 and a high of 96.8% on Dec 31, 2022.
